

Alastair J Noyce

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8630324/publications.pdf>

Version: 2024-02-01

97
papers

6,128
citations

126907

33
h-index

85541

71
g-index

127
all docs

127
docs citations

127
times ranked

7628
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology, The</i> , 2019, 18, 1091-1102.	10.2	1,414
2	Meta-analysis of early nonmotor features and risk factors for Parkinson disease. <i>Annals of Neurology</i> , 2012, 72, 893-901.	5.3	607
3	Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. <i>Lancet Neurology, The</i> , 2015, 14, 57-64.	10.2	487
4	Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α -synuclein mechanisms. <i>Movement Disorders</i> , 2019, 34, 866-875.	3.9	258
5	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology, The</i> , 2015, 14, 1002-1009.	10.2	179
6	Association between diabetes and subsequent Parkinson disease. <i>Neurology</i> , 2018, 91, e139-e142.	1.1	171
7	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. <i>Brain</i> , 2014, 137, 2480-2492.	7.6	169
8	Constipation preceding Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 710-716.	1.9	152
9	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. <i>PLoS Medicine</i> , 2017, 14, e1002314.	8.4	152
10	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. <i>Brain</i> , 2020, 143, 234-248.	7.6	149
11	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019, 34, 1839-1850.	3.9	122
12	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2019, 85, 470-481.	5.3	118
13	Bone health in Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1159-1166.	1.9	114
14	Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. <i>Movement Disorders</i> , 2021, 36, 1420-1429.	3.9	108
15	The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 775-789.	2.8	101
16	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 31-37.	1.9	90
17	Challenges of modifying disease progression in prediagnostic Parkinson's disease. <i>Lancet Neurology, The</i> , 2016, 15, 637-648.	10.2	78
18	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. <i>Lancet Neurology, The</i> , 2016, 15, 585-596.	10.2	77

#	ARTICLE	IF	CITATIONS
19	Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentations. <i>Movement Disorders</i> , 2019, 34, 480-486.	3.9	69
20	No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. <i>Journal of Neurology</i> , 2018, 265, 1089-1095.	3.6	67
21	BMI and low vitamin D are causal factors for multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	67
22	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 219-226.	3.9	59
23	Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1046-1054.	1.9	59
24	Ethnic Variation in the Manifestation of Parkinson's Disease: A Narrative Review. <i>Journal of Parkinson's Disease</i> , 2020, 10, 31-45.	2.8	56
25	Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , 2021, 36, 106-117.	3.9	54
26	Infection and Risk of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 31-43.	2.8	54
27	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. <i>PLoS ONE</i> , 2014, 9, e96260.	2.5	52
28	Technologies Assessing Limb Bradykinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 65-77.	2.8	50
29	The Parkinson's Disease Mendelian Randomization Research Portal. <i>Movement Disorders</i> , 2019, 34, 1864-1872.	3.9	50
30	Viral hepatitis and Parkinson disease. <i>Neurology</i> , 2017, 88, 1630-1633.	1.1	47
31	Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease. <i>Annals of Neurology</i> , 2018, 84, 191-199.	5.3	43
32	Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1251-1255.	2.2	41
33	The Impact of COVID-19 on Access to Parkinson's Disease Medication. <i>Movement Disorders</i> , 2020, 35, 2129-2133.	3.9	40
34	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 89, 803-812.	5.3	38
35	Screening performance of abbreviated versions of the UPSIT smell test. <i>Journal of Neurology</i> , 2019, 266, 1897-1906.	3.6	37
36	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 65-71.	2.2	34

#	ARTICLE	IF	CITATIONS
37	The Parkinsonâ€™s phenomeâ€™ traits associated with Parkinsonâ€™s disease in a broadly phenotyped cohort. <i>Npj Parkinson's Disease</i> , 2019, 5, 4.	5.3	34
38	Gene-Environment Interactions in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	32
39	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 35-42.	5.3	29
40	Nonsyndromic Parkinson disease in a family with autosomal dominant optic atrophy due to <i>OPA1</i> mutations. <i>Neurology: Genetics</i> , 2017, 3, e188.	1.9	27
41	The motor prodromes of parkinsonâ€™s disease: from bedside observation to large-scale application. <i>Journal of Neurology</i> , 2021, 268, 2099-2108.	3.6	27
42	Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuoâ€™perceptual deficits. <i>Movement Disorders</i> , 2018, 33, 544-553.	3.9	25
43	Dopamine reuptake transporterâ€™ singleâ€™photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 478-482.	3.9	25
44	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. <i>JAMA Neurology</i> , 2022, 79, 359.	9.0	25
45	Severe dysphagia as a presentation of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 457-458.	3.9	24
46	Mendelian Randomization â€™ the Key to Understanding Aspects of Parkinson's Disease Causation?. <i>Movement Disorders</i> , 2016, 31, 478-483.	3.9	23
47	The Bradykinesia Akinesia Incoordination (BRAIN) Tap Test: Capturing the Sequence Effect. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 462-469.	1.5	23
48	Developing and assessing a new web-based tapping test for measuring distal movement in Parkinsonâ€™s disease: a Distal Finger Tapping test. <i>Scientific Reports</i> , 2022, 12, 386.	3.3	22
49	Mendelian Randomizationâ€™ A Journey From Obscurity to Center Stage With a Few Potholes Along the Way. <i>JAMA Neurology</i> , 2020, 77, 7.	9.0	21
50	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. <i>Annals of Neurology</i> , 2020, 87, 599-608.	5.3	21
51	Subtle motor disturbances in PREDICT-PD participants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 212-217.	1.9	19
52	Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes. <i>Muscle and Nerve</i> , 2020, 62, 617-625.	2.2	19
53	The Influence of Socioeconomic Deprivation on Dementia Mortality, Age at Death, and Quality of Diagnosis: A Nationwide Death Records Study in England and Wales 2001â€™2017. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 321-328.	2.6	19
54	Tumor Necrosis Factor Inhibition and Parkinson Disease. <i>Neurology</i> , 2021, 96, e1672-e1679.	1.1	17

#	ARTICLE	IF	CITATIONS
55	Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosis. <i>Brain Communications</i> , 2020, 2, fcaa119.	3.3	16
56	Unhealthy Behaviours and Risk of Parkinson's Disease: A Mendelian Randomisation Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1981-1993.	2.8	16
57	Big data, machine learning and artificial intelligence: a neurologist's guide. <i>Practical Neurology</i> , 2020, , practneurol-2020-002688.	1.1	14
58	The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 285-290.	3.6	13
59	Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. <i>Npj Parkinson's Disease</i> , 2021, 7, 33.	5.3	13
60	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. <i>Lancet Regional Health - Europe</i> , The, 2022, 15, 100321.	5.6	13
61	Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization. <i>Annals of Neurology</i> , 2020, 88, 1043-1047.	5.3	11
62	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort. <i>Movement Disorders</i> , 2020, 35, 1658-1662.	3.9	11
63	Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 394-398.	1.5	11
64	Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors. <i>Annals of Neurology</i> , 2022, 92, 270-278.	5.3	10
65	Domotics, Smart Homes, and Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, S55-S63.	2.8	7
66	Web-based assessment of Parkinson's prodromal markers identifies GBA variants. <i>Movement Disorders</i> , 2015, 30, 1002-1003.	3.9	6
67	Cryptococcal meningitis in apparently immunocompetent patients: association with idiopathic CD4+ lymphopenia. <i>Practical Neurology</i> , 2018, 18, 166-169.	1.1	6
68	Laughter isn't always the best medicine. <i>BMJ: British Medical Journal</i> , 2018, 363, k4579.	2.3	6
69	Motor Dysfunction as a Prodrome of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1067-1073.	2.8	6
70	Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson's Disease and Idiopathic Anosmia. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1901-1915.	2.8	6
71	Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity. <i>Movement Disorders</i> , 2022, 37, 427-428.	3.9	6
72	A population scale analysis of rare SNCA variation in the UK Biobank. <i>Neurobiology of Disease</i> , 2021, 148, 105182.	4.4	5

#	ARTICLE	IF	CITATIONS
73	Age-specific effects of childhood body mass index on multiple sclerosis risk. <i>Journal of Neurology</i> , 2022, 269, 5052-5060.	3.6	5
74	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. <i>Npj Parkinson's Disease</i> , 2021, 7, 87.	5.3	4
75	Brain health: The hidden casualty of a humanitarian crisis. <i>Lancet Regional Health - Europe</i> , The, 2022, 15, 100374.	5.6	4
76	Isolated REM sleep behaviour disorder: current diagnostic procedures and emerging new technologies. <i>Journal of Neurology</i> , 2022, 269, 4684-4695.	3.6	4
77	No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 801-809.	2.8	3
78	Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1967-1972.	3.9	3
79	Teaching Neuro Images : Microhemorrhages resulting from cranial radiotherapy in childhood. <i>Neurology</i> , 2010, 75, e2-3.	1.1	2
80	Systematic review and meta-analysis of salivary protein concentration in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1971-1972.	3.9	2
81	Parkinson's Disease: Basic Pathomechanisms and a Clinical Overview. <i>Advances in Neurobiology</i> , 2017, 15, 55-92.	1.8	2
82	Surveying Global Availability of Parkinson's Disease Treatment. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1023-1034.	2.8	2
83	No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210757.	3.0	2
84	Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1605-1609.	2.8	2
85	Observations on a 2-Step Approach to Screening for Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 1506.	9.0	1
86	A novel capsule-based smell test fabricated via coaxial dripping. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20210039.	3.4	1
87	Mild parkinsonian signs: the interface between aging and Parkinson's disease. <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 0, 20, .	0.1	1
88	The potential utility of smell testing to screen for neurodegenerative disorders. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 139-148.	3.1	1
89	Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism. <i>Movement Disorders</i> , 2022, 37, 478-478.	3.9	1
90	Rapid-onset flaccid paraplegia caused by multiple myeloma dumbbell tumour. <i>Practical Neurology</i> , 2014, 14, 268-269.	1.1	0

#	ARTICLE	IF	CITATIONS
91	Regarding: Nicotinic acetylcholine receptors $\hat{I}\pm 7$ and $\hat{I}\pm 9$ modify tobacco smoke risk for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852096994.	3.0	0
92	Genetic Risk of Alzheimer's Disease â€“ Sleepless with the Enemy. <i>Annals of Neurology</i> , 2021, 89, 27-29.	5.3	0
93	Speech-in-noise perception is a marker of preclinical Alzheimerâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A91.1-A91.	1.9	0
94	244â€™... Idiopathic anosmia with motor impairment â€“ a unique prodrome of Parkinsonâ€™s?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A83.4-A84.	1.9	0
95	026â€™... Gene-environment interactions in multiple sclerosis: a UK Biobank study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A21.3-A22.	1.9	0
96	Ethnic and socioeconomic determinants of dementia risk: a nested case-control study in East London. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A8.2-A8.	1.9	0
97	003â€™... Neuroanatomical signatures of genetic risk for Alzheimerâ€™s disease in healthy adults. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A101.3-A102.	1.9	0